We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Genomic Data Integral to Drug Safety Assessments, EMA Says
Genomic Data Integral to Drug Safety Assessments, EMA Says
The European Medicines Agency is asking drug companies to keep pharmacogenomics in mind when doing pre- and postauthorization safety assessments, noting that the selection of biomarkers is key to maintaining a robust safety profile as part of pharmacovigilance activities.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor